Ardelyx (ARDX) Share-based Compensation (2013 - 2026)
Ardelyx's (ARDX) quarterly Share-based Compensation came in at -$3.6 million in Q3 2025, down 573.44% YoY from $753000.0 in Q3 2024, and up 56.57% on a QoQ basis from -$8.2 million in Q2 2025.
Ardelyx (ARDX) Share-based Compensation (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 13 years of Share-based Compensation data on file, last reported at -$3.6 million in Q3 2025.
- Quarterly Share-based Compensation fell 573.44% year-over-year to -$3.6 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (down 189.88% YoY) and the FY2025 annual result came in at $315000.0, down 68.81% from the prior year.
- Share-based Compensation advanced to -$3.6 million in Q3 2025, from -$8.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $12.1 million in Q1 2025 to a low of -$9.3 million in Q4 2023.
- A 5-year average of $192235.3 and a median of $1.4 million in 2021 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation soared 152.98% — and 2025, when it slumped 3293.77%.
- Tracing ARDX's Share-based Compensation over 5 years: stood at $1.4 million in 2021, then plunged by 127.58% to -$390000.0 in 2022, then sank by 2274.62% to -$9.3 million in 2023, then jumped by 108.13% to $753000.0 in 2024, then sank by 573.44% to -$3.6 million in 2025.
- The last three Share-based Compensation figures came in at -$3.6 million (Q3 2025), -$8.2 million (Q2 2025), and $12.1 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 15.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.32 Mn |
| Jun 30, 2026 | 15.32 Mn |
| Mar 31, 2026 | 14.16 Mn |
| Mar 31, 2026 | 14.16 Mn |
| Dec 31, 2025 | 12.45 Mn |
| Dec 31, 2025 | 12.45 Mn |
| Sep 30, 2025 | -3.57 Mn |
| Sep 30, 2025 | -3.57 Mn |
| Jun 30, 2025 | -8.21 Mn |
| Jun 30, 2025 | -8.21 Mn |
| Mar 31, 2025 | 12.09 Mn |
| Mar 31, 2025 | 12.09 Mn |
| Sep 30, 2024 | 753,000.00 |
| Sep 30, 2024 | 753,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Dec 31, 2023 | -9.26 Mn |
| Dec 31, 2023 | -9.26 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Sep 30, 2023 | 3.49 Mn |